Clinical trial
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus…
NCT00144300 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00144300 |
|---|---|
| Title | Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients |
| Official title | A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Drug |
| Interventions | Mirapex, Requip |
| Enrollment | 246 |
| Start date | Jan 1, 2005 |
| Primary completion | Sep 1, 2010 |
| First posted | Sep 5, 2005 |
| Last update posted | Mar 14, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: